RVMD Earnings

RVMD reported its FY2025Q4 earnings on 2026-02-26, showcasing a revenue of 0.00 against an estimate of 13.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -1.56 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following RVMD's FY2025Q4 earnings announcement on 2026-02-26, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, RVMD's stock price tends to shift by an average of -3.66% in the 10 days leading up to earnings and +4.27% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate RVMD’s annual revenue to reach 3.00M, while the EPS is projected at -2.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -8.88% and EPS estimates Revise Upward by 71.87% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between RVMD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -8.88%, while EPS estimates moved Revise Upward by 71.87% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, RVMD's stock price typically moves by -3.66% in the 10 days before its earnings and +4.27% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -2.00 and revenue of 3.00M.

The earnings call presents a mixed sentiment. The company's financial outlook shows a significant projected net loss, which is negative. However, there is strong product development with multiple trials underway, a positive partnership with Royalty Pharma, and potential for new market opportunities. The Q&A section highlights some uncertainties, such as unclear responses on trial event rates and efficacy thresholds, which dampen the overall sentiment. Given these mixed signals, a neutral stock price movement is expected over the next two weeks.